EDSANasdaqPharmaceutical PreparationsUS GAAP · USD

Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and eventually commercializing therapies for inflammatory and immune-related diseases. Its pipeline is centered on two areas: medical dermatology, including EB06 for vitiligo and EB01 for chronic allergic contact dermatitis, and respiratory disease, including EB05 (paridiprubart) for acute respiratory distress syndrome and related indications.

Kysy yhtiöstä
Liikevoitto (EBIT)−7,9milj. USD
−12,8 %v/v
Nettotulos−7,2milj. USD
−16,5 %v/v
Vapaa kassavirta−7,3milj. USD
−49,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−25−20−15−10−505milj. USD2020: 0,33 milj. USD2020: EBIT −6,4 milj. USD20202021: 0,00 milj. USD2021: EBIT −24 milj. USD20212022: EBIT −18 milj. USD20222023: EBIT −9,2 milj. USD20232024: EBIT −7,0 milj. USD20242025: EBIT −7,9 milj. USD2025−7,9
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Edesa Biotech, Inc.

Liiketoiminta

Osuus liikevaihdosta
Medical Dermatology45 %

Pipeline assets aimed at autoimmune and inflammatory skin diseases, including vitiligo and allergic contact dermatitis.

Respiratory / Host-Directed Therapeutics45 %

Clinical programs targeting severe respiratory inflammation and ARDS, led by EB05 (paridiprubart).

Licensing and Partnering10 %

Out-licensing or collaboration arrangements for assets that are not being commercialized directly.

Asiakkaat

Edesa does not yet have commercial customers because it is still in clinical development and has not launched approved products. Its future buyers would likely include hospitals, physicians, and healthcare systems if its candidates receive approval, while licensing partners could become important counterparties for assets such as EB01. Government agencies and grant programs also matter as non-customer funding and development partners.

No commercial customers yet

The company is clinical-stage and has no marketed products, so it does not currently sell investigational medicines to end users.

Healthcare providers and hospitals

If approved, physicians, hospitals, and health systems would prescribe or administer EB06 and EB05 for vitiligo and ARDS patients.

Pharmaceutical licensing partners

Potential partners may acquire regional rights or co-develop EB01 and other assets to provide commercialization infrastructure.

Government and grant agencies

Public-sector programs fund parts of EB05 development and reimburse eligible R&D expenses, supporting the pipeline.

Strategia

Edesa’s strategy is to advance a small number of mechanistically differentiated drug candidates through proof-of-concept and later-stage clinical development, then either commercialize them selectively or partner them out. The company is prioritizing indications with unmet medical need and large addressable markets, while using licensing, collaboration, grants, and equity financing to fund development. It is also evaluating additional product acquisitions and in-licensing to broaden the pipeline.

Advance EB06 into Phase 2 proof-of-conceptLyhyt aikaväli

Vitiligo is a clear clinical target and a successful study would strengthen the dermatology pipeline.

Develop and partner EB01Lyhyt aikaväli

EB01 is Phase 3-ready and partnering can provide capital and commercialization reach without building a full sales force.

Expand EB05 clinical and partnering opportunitiesKeskipitkä aikaväli

Positive ARDS data can create a path to regulatory discussions, government support, and broader respiratory indications.

Secure additional capital and non-dilutive fundingLyhyt aikaväli

The company disclosed going-concern uncertainty and needs funding to continue development.

Maantiede

Edesa is headquartered in Ontario, Canada, and operates through subsidiaries in Canada and the United States. Its development and future commercialization plans are focused on North America first, with the company also discussing potential partnerships for regions outside North America, including Europe. The business is therefore exposed to Canadian and U.S. regulatory pathways, grant funding, and future market-access decisions.

Riskit

Edesa faces the classic risks of a clinical-stage biotech: no product revenue, dependence on capital markets, and uncertainty around clinical and regulatory outcomes. Its disclosures also highlight dependence on third-party manufacturers, CROs, and potential commercialization partners, which can delay programs or raise costs. Because it is pre-commercial and still funding development, any setback in trials, approvals, or financing could materially affect viability.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and financing risk1Clinical development failure2Regulatory approval delays3Third-party manufacturing and clinical operations dependence4Commercialization and reimbursement risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company states existing cash and expected reimbursements may not fund operations for 12 months without additional capital or reduced spending.

    Kohdistuu: Corporate liquidity and pipeline continuity

  2. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    EB06, EB01, and EB05 are still in development, so negative data would reduce or eliminate future value.

    Kohdistuu: Pipeline assets

  3. Regulatory approval delaysVaikutus: KorkeaTodennäköisyys: Korkea

    The company must obtain FDA, Health Canada, or other approvals before commercialization, and timelines are uncertain.

    Kohdistuu: EB06 and EB05 programs

  4. Third-party manufacturing and clinical operations dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on external manufacturers and trial operators, creating execution and supply risk.

    Kohdistuu: Clinical supply and trial timelines

  5. Commercialization and reimbursement riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Even if approved, products may face pricing pressure and reimbursement barriers that limit uptake.

    Kohdistuu: Future marketed products

Kysy Clarifolta: Edesa Biotech, Inc.

Kirjanpito

Harkinnanvaraiset erät
Grant income recognition

Government reimbursements under the 2023 SIF agreement are recorded in other income and can offset R&D expense.

Vaikutus: Affects reported operating loss and comparability across periods

Clinical trial and R&D accrual estimates

External research costs and trial-related obligations require management estimates and can change with program timing.

Vaikutus: Can move quarterly R&D expense materially

Foreign exchange translation

The company operates in Canada and the U.S., so currency movements affect reported results and cash balances.

Vaikutus: Creates volatility in other income/expense

Going-concern disclosure

Management concluded substantial doubt exists about continuing as a going concern without additional financing or spending cuts.

Vaikutus: Important for liquidity assessment and valuation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Editas Medicine, Inc.

EDIT · Biological Products, (No Diagnostic Substances)

Viridian Therapeutics, Inc.

VRDN · Pharmaceutical Preparations

EyePoint, Inc.

EYPT · Laboratory Analytical Instruments

ImageneBio, Inc.

IMA · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026